Novo Nordisk’s Pipeline Progress and Pill Milestone Fail to Budge Stock From 46% Below High
Despite a 46.86% drop from its 52-week high, Novo Nordisk reports strong Wegovy pill uptake, promising clinical data,…
Browsing Tag